ERBB2 and inflammatory breast carcinoma: Another Humanized IgG1 that targets ErbB2/Her2 is Pertuzumab (Perjeta), which in the UK is licensed for Her2-positive breast cancer to be used in combination with trastuzumab and chemotherapy for neoadjuvant treatment of locally advanced breast cancer or inflammatory breast cancer or early breast cancer with high recurrence rate.